The numbers
Statistics derived by joining CMS pricing files and FDA enforcement records: closeout rates on GLP-1 warning letters, inspection status across the 503B register, and acquisition cost per package rather than per millilitre.
By Sam Reed · Founder and data lead
8 pages
In this section
40 of 98 registered 503B outsourcing facilities have never been inspected55 of 58 inspected 503B facilities received a Form 483129 of 149 FDA warning letters naming a GLP-1 came in the last 12 months6 of 47 GLP-1 telehealth programmes have received an FDA warning letter39 of 103 GLP-1 packages have a federal acquisition cost, priced per penState Medicaid programmes reimbursed 22.1 million GLP-1 prescriptions in 2025Medicare Part D paid $27.0 billion for GLP-1 medications in 2024Only 20 of 43 GLP-1 telehealth programmes ship to all 50 states
Data sources · cited with retrieval dates
- CMS NADACNational Average Drug Acquisition Cost, weekly file
- CMS Medicare Part DPrescriber public use file, by geography and drug
- CMS State Drug UtilizationQuarterly Medicaid prescription and reimbursement data
NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.